GMED Quote, Financials, Valuation and Earnings

Enovis has a net margin of 12.62% compared to Globus Medical's net margin of -10.02%. Globus Medical's return on equity of 4.59% beat Enovis's return on equity of -26.77%.

Globus Medical has a consensus price target of $85.17, signalling upside risk potential of 40.61%. On the other hand Enovis has an analysts' consensus of $56.50 which suggests that it could grow by 68.86%. Given that Enovis has higher upside potential than Globus Medical, analysts believe Enovis is more attractive than Globus Medical.

Globus Medical has a beta of 1.193, which suggesting that the stock is 19.307% more volatile than S&P 500. In comparison Enovis has a beta of 1.494, suggesting its more volatile than the S&P 500 by 49.355%.

Globus Medical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Enovis offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Globus Medical pays -- of its earnings as a dividend. Enovis pays out -- of its earnings as a dividend.

Globus Medical quarterly revenues are $598.1M, which are larger than Enovis quarterly revenues of $558.8M. Globus Medical's net income of $75.5M is higher than Enovis's net income of -$56M. Notably, Globus Medical's price-to-earnings ratio is 45.20x while Enovis's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Globus Medical is 3.34x versus 0.87x for Enovis. Usually stocks with elevated PS ratios are considered overvalued.

Integer Holdings has a net margin of 12.62% compared to Globus Medical's net margin of -5.14%. Globus Medical's return on equity of 4.59% beat Integer Holdings's return on equity of 4.85%.

Globus Medical has a consensus price target of $85.17, signalling upside risk potential of 40.61%. On the other hand Integer Holdings has an analysts' consensus of $148.75 which suggests that it could grow by 22.74%. Given that Globus Medical has higher upside potential than Integer Holdings, analysts believe Globus Medical is more attractive than Integer Holdings.

Globus Medical has a beta of 1.193, which suggesting that the stock is 19.307% more volatile than S&P 500. In comparison Integer Holdings has a beta of 0.980, suggesting its less volatile than the S&P 500 by 1.988%.

Globus Medical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Integer Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Globus Medical pays -- of its earnings as a dividend. Integer Holdings pays out -- of its earnings as a dividend.

Globus Medical quarterly revenues are $598.1M, which are larger than Integer Holdings quarterly revenues of $437.4M. Globus Medical's net income of $75.5M is higher than Integer Holdings's net income of -$22.5M. Notably, Globus Medical's price-to-earnings ratio is 45.20x while Integer Holdings's PE ratio is 57.44x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Globus Medical is 3.34x versus 2.44x for Integer Holdings. Usually stocks with elevated PS ratios are considered overvalued.

Insulet has a net margin of 12.62% compared to Globus Medical's net margin of 6.22%. Globus Medical's return on equity of 4.59% beat Insulet's return on equity of 36.9%.

Globus Medical has a consensus price target of $85.17, signalling upside risk potential of 40.61%. On the other hand Insulet has an analysts' consensus of $336.01 which suggests that it could grow by 11.4%. Given that Globus Medical has higher upside potential than Insulet, analysts believe Globus Medical is more attractive than Insulet.

Globus Medical has a beta of 1.193, which suggesting that the stock is 19.307% more volatile than S&P 500. In comparison Insulet has a beta of 1.346, suggesting its more volatile than the S&P 500 by 34.619%.

Globus Medical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Insulet offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Globus Medical pays -- of its earnings as a dividend. Insulet pays out -- of its earnings as a dividend.

Globus Medical quarterly revenues are $598.1M, which are larger than Insulet quarterly revenues of $569M. Globus Medical's net income of $75.5M is higher than Insulet's net income of $35.4M. Notably, Globus Medical's price-to-earnings ratio is 45.20x while Insulet's PE ratio is 54.25x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Globus Medical is 3.34x versus 10.15x for Insulet. Usually stocks with elevated PS ratios are considered overvalued.

RxSight has a net margin of 12.62% compared to Globus Medical's net margin of -21.61%. Globus Medical's return on equity of 4.59% beat RxSight's return on equity of -10.39%.

Globus Medical has a consensus price target of $85.17, signalling upside risk potential of 40.61%. On the other hand RxSight has an analysts' consensus of $21.18 which suggests that it could grow by 61.2%. Given that RxSight has higher upside potential than Globus Medical, analysts believe RxSight is more attractive than Globus Medical.

Globus Medical has a beta of 1.193, which suggesting that the stock is 19.307% more volatile than S&P 500. In comparison RxSight has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Globus Medical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. RxSight offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Globus Medical pays -- of its earnings as a dividend. RxSight pays out -- of its earnings as a dividend.

Globus Medical quarterly revenues are $598.1M, which are larger than RxSight quarterly revenues of $37.9M. Globus Medical's net income of $75.5M is higher than RxSight's net income of -$8.2M. Notably, Globus Medical's price-to-earnings ratio is 45.20x while RxSight's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Globus Medical is 3.34x versus 3.52x for RxSight. Usually stocks with elevated PS ratios are considered overvalued.